OncLive TV

Dr. Robson on Breast Cancer Risk Management

August 26th 2016

Dr. Suresh S. Ramalingam on Optimizing Immunotherapies in Lung Cancer

August 26th 2016

Dr. Kelly on Immunotherapy Combinations for Patients With NSCLC

August 26th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).

Benefit of Maintenance Olaparib in Patients With Ovarian Cancer

August 25th 2016

Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discusses a study comparing the use of olaparib (Lynparza) after chemotherapy with placebo after chemotherapy in patients with platinum-sensitive ovarian cancer.

Dr. George D. Demetri on the Importance of Collaboration in Sarcoma

August 25th 2016

Dr. Mato on Managing Side Effects With Ibrutinib/Idelalisib in CLL

August 24th 2016

Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Lee on Nanotechnology Combination Therapy in RCC

August 24th 2016

Benjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).

Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast Cancer

August 24th 2016

Dr. Ko on Surgery as an Effective Option for Patients With Endometrial Cancer

August 23rd 2016

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses why surgery is an effective option for patients with endometrial cancer.

Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

August 23rd 2016

Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.

Dr. Keith T. Flaherty on the NEMO Trial in NRAS-Mutant Melanoma

August 23rd 2016

Dr. Elizabeth Plimack on Consideration Regarding Nivolumab in RCC

August 23rd 2016

Dr. Palumbo on Significance of Daratumumab Triplet in Multiple Myeloma

August 22nd 2016

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.

Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC

August 22nd 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising

August 21st 2016

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

August 19th 2016

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Dr. Federman on Challenges With Treating AYA Patients With Sarcoma

August 19th 2016

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma.

Dr. Pecora on Oncology Care Model Innovations

August 19th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Dr. Henricus de Koning on Screening in NSCLC

August 19th 2016

Dr. Baas on Next Steps in the Treatment of Mesothelioma

August 19th 2016

Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.